Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

11.1K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

786
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
786
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

10.7K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.9K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

658
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
658

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

GPR120/free fatty acid receptor 4 (FFAR-4) agonists, antagonists, allosteric modulators: Computational drug design and discovery review.

European journal of medicinal chemistry·2026
Same author

Predictive neural networks accelerate identification of mechanistically validated small-molecule modulators of TLR7 signaling.

Biochemical pharmacology·2026
Same author

Advanced theoretical engineering of KM<sub>3</sub>H<sub>9</sub> (M = Fe, Co, Ni, Cu) hydrides for novel applications in hydrogen storage.

Dalton transactions (Cambridge, England : 2003)·2026
Same author

Multi-criteria based stable clustering technique for vehicular ad-hoc networks.

Scientific reports·2026
Same author

EZH2 inhibition via GSK-126 mitigates EndMT and atherosclerosis in diabetes: A translational epigenetic approach.

Science advances·2026
Same author

Over 600 million people aged 18-65 will have headache tomorrow: global 1-day prevalence and recall bias from a meta-analysis of individual participant data (N = 38,512) from the general populations of 15 countries.

The journal of headache and pain·2026

相关实验视频

Updated: Feb 28, 2026

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

14.8K

生成型人工智能发现了具有潜在抗炎活性的新型Chrebp/Txnip轴抑制剂.

Naila Qayyum1,2, Abdul Waheed Khan1, Muhammad Haseeb2

  • 1Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea.

Journal of chemical information and modeling
|February 26, 2026
PubMed
概括

人工智能识别了针对Chrebp-14-3-3蛋白-蛋白相互作用的新型化合物,这对于2型糖尿病的代谢炎症至关重要. 这些化合物有效地降低了炎症标志物,并保护了胰腺细胞.

更多相关视频

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

2.1K

相关实验视频

Last Updated: Feb 28, 2026

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

14.8K
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

2.1K

科学领域:

  • 生物化学 生物化学
  • 计算化学的计算化学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 2型糖尿病涉及由Chrebp/Txnip轴驱动的代谢炎症,促进NLRP3炎症组合和胰腺β细胞功能障碍.
  • 克雷布p-14-3-3蛋白-蛋白相互作用 (PPI) 是一个相关的治疗标,但仍然未被充分探索,只有很少的已知调节器.

研究的目的:

  • 开发一个人工智能驱动的生成设计框架,以重新发现针对Chrebp-14-3-3相互作用的选择性PPI向化合物.
  • 识别和验证这种PPI的新型小分子调节剂,用于潜在的2型糖尿病治疗方法.

主要方法:

  • 利用一个条件循环神经网络 (QSPR-GEN),在一个大体上进行预训练,并对特定目标数据进行微调,以产生新的化合物.
  • 嵌入了面向选择性的物理化学描述符和基于结构的精细化,专注于一个独特的α-状表位.
  • 采用虚拟选,分子动力学和MM / PBSA计算来优先考虑具有有利能量和药理动力学的领先候选人.

主要成果:

  • 在产生的化合物中,实现了高支架独特性 (94.6%),偏离了杂乱的化学类型.
  • 优先考虑具有良好的结合性和药理动力学特征的候选T2和T7.
  • 候选T7显著抑制了Txnip和NLRP3的表达,降低了IL-1β的分泌,并在代谢应激下减弱了巨细胞的热细胞死亡,超过了参考抑制剂.

结论:

  • 提出了一个强大的计算框架,用于设计具有挑战性的PPI的反向设计.
  • 证明了针对Chrebp-14-3-3相互作用的机械精确的化合物 (T2,T7) 的成功识别和实验验证.
  • 强调了人工智能驱动的方法在发现新型治疗方法的潜力,用于治疗2型糖尿病等代谢疾病.